צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים Allarity Therapeutics, Inc. (ALLR)

Allarity Therapeutics is creating a closed-loop precision medicine ecosystem by combining targeted therapy with AI-driven diagnostics. The quarter-over-quarter EPS trend reflects a financial dependence on investments, as commercial products are still undergoing testing and -104.80 determines the current status of the parameter. The company is implementing innovations that predict tumor response to drugs, eliminating ineffective treatments and saving lives.
Allarity Therapeutics, Inc. (ALLR) - פילוחי מדדים ודוחות פיננסיים

Liquidity shortages and scaling challenges regarding DRP diagnostics at Allarity Therapeutics (ALLR) jeopardize business sustainability until strategic financing is secured. The current value of -104.80 reflects the dynamics of net earnings per share, where a rolling calculation of quarterly growth captures the deviation of actual development rates from targets, allowing for an assessment of the asset's liquidity risks through the quarterly EPS growth rate.